GLP-1 receptor agonists like semaglutide and tirzepatide — already blockbusters for diabetes and obesity — are now being investigated as potential treatments for substance use disorders. A large study of 600,000+ veterans found GLP-1 users had significantly lower risks of developing addiction and fewer overdoses and drug-related deaths. Experts say the drugs may work by blunting the brain's craving signals across all addictive substances, though definitive clinical trial data are still needed.
GLP-1 receptor agonists like semaglutide and tirzepatide have already transformed diabetes and obesity care — and now they may be coming for addiction. Growing preclinical, observational, and early clinical data suggest these drugs reduce cravings across a wide range of substances, including alcohol, nicotine, opioids, cocaine, and methamphetamine. Experts believe GLP-1s may work by modulating the brain's mesolimbic dopamine and reward pathways — not targeting any one substance, but quieting the shared biology of craving itself.
A landmark study of over 600,000 U.S. veterans published in The BMJ found that GLP-1 users had a 14% lower risk of developing any substance use disorder compared to those on other diabetes medications. Among those already struggling with addiction, GLP-1 use was linked to dramatic reductions in serious outcomes. Meanwhile, two randomized trials in alcohol use disorder (AUD) showed semaglutide significantly reduced alcohol consumption and cravings, with a number needed to treat (NNT) of just 4.3 — comparing favorably to currently approved AUD medications.
By the Numbers:
Why it matters: Millions of Americans with substance use disorders lack effective treatment options — especially for stimulant addictions, where no FDA-approved medications exist. If ongoing trials confirm these findings, GLP-1s could represent a paradigm shift: one drug class targeting the common biology of addiction across substances.
